Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Illumina Names Klausner as SVP, CMO


Illumina said this week that it has appointed Richard Klausner as senior vice president and chief medical officer.

Prior to joining Illumina, Klausner was managing partner of venture capital firm The Column Group. He has also served as executive director for global health at the Bill and Melinda Gates Foundation, and as the eleventh director of the National Cancer Institute between 1995 and 2001. Klausner has also been chief of cell biology and metabolism at the National Institute of Child Health and Human Development; past president of the American Society of Clinical Investigation; and chairman of the National Science Education Standards Projects of the National Academy of Sciences. He holds an MD from Duke University.

Gregory Lucier has been appointed to the board of directors at RainTree Oncology and elected chairman of the board at Sanford-Burnham Medical Research Institute.

Lucier is CEO and chairman of Life Technologies. He also serves on the boards of CareFusion, Synthetic Genomics, and Rady Children's Hospital. He holds a BS in engineering from Pennsylvania State University and an MBA from Harvard Business School.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.